The science behind NewDays
The evidence-based methods that inform treatments delivered by NewDays have been consistently supported in clinical trials as improving cognition, quality of life, and independence in people with mild cognitive impairment and dementia, and even delay symptoms of cognitive decline.

Our AI companion, Sunny, is trained on clinical research including the groundbreaking I-CONECT Study led by Dr. Hiroko Dodge of Harvard University. NewDays holds exclusive license to this protocol. For more information about the study see the science behind NewDays.
Ready to get answers?
Schedule your free consultation with a NewDays clinician this week.
Available Monday-Friday via secure video call.









